December 2016
-
Discovery Laboratories has announce the launch of its Afectair airway connector for the delivery of aerosolized medications to infants in neonatal or pediatric intensive care units. The disposable device enables delivery of aerosolized drugs to… Read more . . .
-
The FDA has approved Alexza Pharmaceutical’s Adasuve loxapine inhalation powder for the treatment of agitation in patients with schizophrenia or bipolar I disorder. The Staccato loxapine inhaler will be available only under a Risk Evaluation… Read more . . .
-
Acorda Therapeutics says that it has completed its acquisition of Neuronex, including Neuronex’s diazepam nasal spray formulation, for $6.8 million. The company also announced that it plans to submit a 505(b)(2) NDA in 2013 for… Read more . . .
-
Paul M. Young and Daniela Traini have moved from the Pharmacy Faculty at the University of Sydney to the Woolcock Institute of Medical Research (WIMR) in order to establish a new Respiratory Technology team at… Read more . . .
-
Matrixx Initiatives has voluntarily recalled a single lot of Zicam Extreme Congestion Relief nasal gel spray due to contamination with Burkholderia cepacia in a single sample. Zicam is a homeopathic product available over the counter… Read more . . .
-
GlaxoSmithKline and Theravance say that they have submitted an NDA to the US FDA for an umeclidinium bromide (UMEC)/vilanterol (VI) dry powder inhaler for the treatment of COPD to be marketed under the name “Anoro… Read more . . .
-
SkyePharma has announced that AstraZeneca will pay $8 million in January 2013 “to settle certain disputes” resulting from AZ’s termination of their licensing deal for the Pulmicort MDI. The deal was terminated after AZ discontinued… Read more . . .
-
Copley Scientific has launched a set of tools for inhaler testing qualification called the Flow-Time Verification kit. The kit allows for automatic measurement of flow duration, eliminating the need for stopwatches or the use of… Read more . . .
-
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding Alexza Pharmaceutical’s marketing application for Adasuve Staccato loxapine for the treatment of agitation in… Read more . . .
-
An effort to return remaining units of Primatene Mist epinephrine inhalers to the market failed in the US House of Representatives on December 12, 2012 by a vote of 229-182. Primatene Mist, a CFC-propelled MDI… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland